Fitknees by Ashva

Fitknees is India's most comprehensive AI-powered knee health diagnostic wearable, conducting 10 clinical tests in 10 minutes to generate a detailed KneePort report that identifies the root cause of knee problems. Unlike X-rays and MRIs (which show structural anatomy), Fitknees assesses functional capacity: how well the knee actually performs during movement, not just how it looks on a scan. The 10-test protocol covers both motor examination (Range of Motion, Proprioception, Muscle Strength, Static Balance) and functional examination (Dynamic Balance, Staircase Climbing, 6-Minute Walk, Gait Analysis), plus the Oxford Knee Pain Score (12 subjective questions capturing the patient's pain experience). This comprehensive assessment provides physiotherapists with a data-driven baseline for creating personalised recovery plans and objectively tracking progress over time.

Amount Asked: ₹50 lakhs Equity Offered: 1.25% Implied Pre-Money Valuation: ₹40 crore

Anmol Ajay Saxena is Season 4's most personally pain-motivated medtech founder. Her founding story begins with two parallel knee health crises: her own knee pain during a weight-loss journey in college, and her mother's 8-year battle with chronic knee problems requiring continuous physiotherapy. These dual experiences gave Anmol both the patient's perspective (understanding the frustration of unclear diagnoses and slow recovery) and the caregiver's perspective (understanding the emotional and financial toll of long-term knee treatment). "I wanted to create a solution that would empower people to take control of their knee health," Anmol explained on the Shark Tank stage. The concept originated during a college hackathon, where she first envisioned a wearable device that could diagnose knee problems objectively. After graduation, she joined Ford Motors to build financial stability, spending 2.5 years in automotive engineering before her entrepreneurial dream became impossible to suppre

Fitknees is India's most comprehensive AI-powered knee health diagnostic wearable, conducting 10 clinical tests in 10 minutes to generate a detailed KneePort report that identifies the root cause of knee problems. Unlike X-rays and MRIs (which show structural anatomy), Fitknees assesses functional capacity: how well the knee actually performs during movement, not just how it looks on a scan. The 10-test protocol covers both motor examination (Range of Motion, Proprioception, Muscle Strength, Static Balance) and functional examination (Dynamic Balance, Staircase Climbing, 6-Minute Walk, Gait Analysis), plus the Oxford Knee Pain Score (12 subjective questions capturing the patient's pain experience). This comprehensive assessment provides physiotherapists with a data-driven baseline for creating personalised recovery plans and objectively tracking progress over time.

Kunal Bahl opted out citing scalability concerns. The premium pricing (₹7.5 lakhs per combo) limited the addressable market to well-funded hospitals and large physiotherapy chains. Peyush Bansal declined to invest for similar scalability reasons. The B2B medical device market's long sales cycles and hospital procurement complexity sat outside his consumer brand expertise. Vineeta Singh did not invest, sharing concerns about the niche medical device category's growth trajectory and the ₹40 crore valuation. Namita Thapar was the most domain-aligned Shark: Emcure's pharmaceutical healthcare ecosystem, hospital distribution network, and clinical validation methodology were directly applicable to scaling a medical wearable across India's hospital system. She co-invested with Anupam. Anupam Mittal personally experienced the product (taking the knee test on stage), giving him first-hand conviction in its diagnostic accuracy.

Anmol asked ₹50L for 1.25% (₹40 crore). Three Sharks exited (Kunal, Peyush, Vineeta on scalability and pricing). Namita and Anupam jointly offered ₹50 lakhs for 4% equity (₹12.5 crore valuation). Anmol accepted. The valuation dropped 69% from ₹40 crore to ₹12.5 crore, and equity diluted 3.2x from 1.25% to 4%, but the founder secured the most medtech-relevant two-Shark combination on the panel: pharmaceutical healthcare distribution (Namita) plus digital platform scaling (Anupam).

Anmol Ajay Saxena accepted the two-Shark deal from Namita Thapar and Anupam Mittal at ₹50 lakhs for 4% equity, valuing Ashva at ₹12.5 crore. The deal brought Emcure's pharmaceutical hospital network, clinical distribution channels, and healthcare regulatory expertise (Namita) and Shaadi.com's consumer platform scaling methodology and digital health potential (Anupam) into India's most advanced AI-powered knee health diagnostic company. Anupam's personal experience with the product on stage created the specific experiential conviction that no pitch deck could replicate.

"Ashva experienced a 30% spike in hospital inquiries immediately after the Shark Tank episode aired. The combination of Anupam's on-stage knee test (creating viral content) and Namita's healthcare endorsement (providing institutional credibility) generated awareness among orthopedic surgeons, physiotherapists, and hospital administrators who had never heard of Fitknees before the episode. The company's devices are deployed across 115 plus hospitals and physiotherapy centres, including Apollo (India's largest hospital chain), Manipal Hospitals, Aster Hospitals, and Yashoda Hospital. Each deployment generates ongoing revenue through device sales, maintenance contracts, and potential software subscription fees for KneePort report analytics."